IL7 and cancer: These cytokines were recently described to recruit and activate CD56+ cells for an innate immune response [51,52,53] and were secreted independently of engineering IL7/IL12 secretion and may activate non-specific cytotoxicity against cancer cells that is further boosted by IL12 of engineered MSC.